Table 1.
Patients at time 1 and time 2: rating scale measures, medication at time 2, and improvement status (1 = improved, 2 = not improved).
| Time 1 | Medication (at time 2, daily dose) | Time 2 | % change in CDSS score | Improved? | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| BDI | SSAI | CDSS | Timelag (days) | BDI | SSAI | CDS (State) | ||||
| 1 | 1 | 26 | 475 | 180 | Lamotrigine 400 mg | 0 | 26 | 140 | −70.5 | 1 |
| 2 | 27 | 58 | 780 | 242 | Lamotrigine 400 mg | 30 | 66 | 1175 | +50.6 | 2 |
| 3 | 1 | 39 | 985 | 180 | Lamotrigine 300 mg | 3 | 31 | 615 | −37.6 | 1 |
| 4 | 6 | 38 | 295 | 154 | Lamotrigine 200 mg | 10 | 46 | 285 | −3.4 | 2 |
| 5 | 15 | 47 | 700 | – | – | – | – | – | – | – |
| 6 | 14 | 42 | 520 | – | – | – | – | – | – | – |
| 7 | 3 | 32 | 589 | 223 | Lamotrigine 400 mg | 4 | 37 | 237 | −59.8 | 1 |
| 8 | 4 | 44 | 685 | 221 | Lamotrigine 250 mg | 4 | 55 | 344 | −49.8 | 1 |
| 9 | 21 | 54 | 1355 | – | – | – | – | – | – | – |
| 10 | 10 | 57 | 591 | – | – | – | – | – | – | – |
| 11 | 6 | 29 | 467 | 127 | Lamotrigine 250 mg | 11 | 27 | 564 | +20.8 | 2 |
| 12 | 18 | 50 | 1007 | 119 | Lamotrigine 400 mg | 17 | 53 | 1608 | +59.7 | 2 |
| Venlafaxine 75 mg | ||||||||||
| 13 | 9 | 47 | 529 | 205 | Lamotrigine 400 mg | 9 | 46 | 588 | +11.2 | 2 |
| 14 | 7 | 37 | 696 | 158 | Lamotrigine 300 mg | 5 | 22 | 260 | −62.6 | 1 |
| Fluoxetine 20 mg | ||||||||||
| Mean | 10.14 | 42.86 | 691.00 | 180.9 | – | 9.3 | 40.9 | 581.6 | – | – |
| SD | 7.86 | 10.03 | 272.42 | 41.74 | – | 8.77 | 14.58 | 467.70 | – | – |
Timelag, number of days between time 1 and time 2; BDI, Beck Depression Inventory; SSAI, Spielberger State Anxiety Inventory; DES, Dissociative Experiences Scale; CDS, Cambridge Depersonalization Scale (State Version). All 14 patients were scanned at time 1. Time 2 columns indicate which patients were subsequently re-scanned (10 of 14).